News

News 27.10.2026 ZURICH, Switzerland — October 26, 2026 — AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced new analyses from its global Phase 2 clinical trial (AP101-02) evaluating the company’s Phase...

News 26.10.2026 Zurich, 23 October  2026 – The auditing and consulting firm EY Switzerland’s Entrepreneur Of The Year 2026 award – the 29th year of the program – has been presented to Swiss business personalities in recognition of their innovation and commitment. Stefan Rösch-Rütsche, EY Switzerland’s Country Managing Partner, commented: “Swiss entrepreneurs make...

News 22.10.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the selection of MP0730 as its lead Radio-DARPin candidate targeting the...

News 21.10.2026 As CMO, Adam will oversee Kuros's global medical and clinical affairs, strengthening the generation of clinical evidence, advancing scientific strategy, and deepening physician engagement. He brings a unique perspective to the industry, with extensive experience in orthopedic spine surgery, clinical research, and strategic business leadership. His career includes academic medicine...

News 16.10.2026 Kuros Biosciences increases 2026 annual guidance The company reports 40% year-over-year increase in sales in the first nine months of 2026 Schlieren (Zurich), Switzerland, October 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial performance for the first nine months...